SG11201507061XA - Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction - Google Patents
Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunctionInfo
- Publication number
- SG11201507061XA SG11201507061XA SG11201507061XA SG11201507061XA SG11201507061XA SG 11201507061X A SG11201507061X A SG 11201507061XA SG 11201507061X A SG11201507061X A SG 11201507061XA SG 11201507061X A SG11201507061X A SG 11201507061XA SG 11201507061X A SG11201507061X A SG 11201507061XA
- Authority
- SG
- Singapore
- Prior art keywords
- selenium
- disease
- prevention
- compositions
- treatment
- Prior art date
Links
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 title 1
- 230000006806 disease prevention Effects 0.000 title 1
- 230000004065 mitochondrial dysfunction Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229910052711 selenium Inorganic materials 0.000 title 1
- 239000011669 selenium Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361788133P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/029328 WO2014144776A1 (en) | 2013-03-15 | 2014-03-14 | Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201507061XA true SG11201507061XA (en) | 2015-10-29 |
Family
ID=51537786
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201507061XA SG11201507061XA (en) | 2013-03-15 | 2014-03-14 | Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction |
| SG10202101918RA SG10202101918RA (en) | 2013-03-15 | 2014-03-14 | Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202101918RA SG10202101918RA (en) | 2013-03-15 | 2014-03-14 | Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9833486B2 (en) |
| EP (1) | EP2968404A4 (en) |
| JP (1) | JP6313418B2 (en) |
| KR (1) | KR102245702B1 (en) |
| CN (3) | CN105377271A (en) |
| AU (1) | AU2014228785B2 (en) |
| BR (1) | BR112015022514A2 (en) |
| CA (1) | CA2903845C (en) |
| CL (1) | CL2015002677A1 (en) |
| HK (1) | HK1216506A1 (en) |
| MX (1) | MX359626B (en) |
| RU (1) | RU2663127C2 (en) |
| SG (2) | SG11201507061XA (en) |
| WO (1) | WO2014144776A1 (en) |
| ZA (1) | ZA201506759B (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2015011462A (en) | 2013-03-14 | 2016-05-31 | Jerome J Schentag | Cholestosome vesicles for incorporation of molecules into chylomicrons. |
| HUE051713T2 (en) * | 2014-03-14 | 2021-03-29 | Alltech Inc | Compositions of selenoorganic compounds and methods of use thereof |
| CA2981138A1 (en) | 2015-03-27 | 2016-10-06 | The Research Foundation For The State University Of New York | Methods and materials for reducing amyloid beta levels within a mammal |
| WO2017048252A1 (en) * | 2015-09-15 | 2017-03-23 | Alltech, Inc. | Compositions of selenoorganic compounds and methods of use thereof |
| CA3017763A1 (en) * | 2016-03-14 | 2017-09-21 | Mitogenetics, Llc | Materials and methods for treating hypoxic conditions |
| EP3624809A4 (en) | 2017-05-19 | 2021-03-03 | Alltech, Inc. | Pharmaceutical agents, compositions, and methods relating thereto |
| CN108283711A (en) * | 2018-05-06 | 2018-07-17 | 冷立娟 | A kind of instant particles as Chinese medicine and preparation method thereof for treating alcoholic myocardiopathy |
| CN109820933A (en) * | 2019-02-27 | 2019-05-31 | 北京曲佳科技有限公司 | Weight-reducing tablet and preparation method thereof |
| CN111493325A (en) * | 2020-05-07 | 2020-08-07 | 恩施德源健康科技发展有限公司 | Application of plant selenium peptide in preparation of composition for improving obesity and metabolic syndrome |
| CN112129864B (en) * | 2020-09-24 | 2022-04-01 | 江南大学 | Method for determining selenium form in selenium-rich plant dry powder |
| KR102328808B1 (en) * | 2020-12-02 | 2021-11-22 | 동의대학교 산학협력단 | Composition for preventing and improving sarcopenia using brewer's yeast |
| CN114053298A (en) * | 2021-11-19 | 2022-02-18 | 华中农业大学 | Medicine for inhibiting myocardial hypertrophy and construction method of model |
| CN114235989A (en) * | 2021-11-27 | 2022-03-25 | 山东省烟台市农业科学研究院 | High performance liquid chromatography for determining content of asomate |
| CN114031650B (en) * | 2021-11-29 | 2023-05-02 | 上海交通大学 | Chitosan oligosaccharide selenium coordination compound and preparation method and application thereof |
| CN114931569B (en) * | 2022-06-22 | 2023-05-16 | 中国农业科学院油料作物研究所 | Application of methylselenocysteine in preparation of product for improving male reproductive capacity |
| CN116333302B (en) * | 2023-03-31 | 2024-09-10 | 中南大学 | Stable and durable antioxidant nano-dot and application thereof in type II diabetes |
| CN116421618B (en) * | 2023-06-15 | 2023-09-29 | 暨南大学 | Preparation method of Se@NADH and application of Se@NADH in spinal cord injury treatment |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5896024A (en) * | 1981-10-16 | 1983-06-07 | リチヤ−ド・エフ・ストツケル | Platinum toxicity detoxicant |
| WO2004107881A1 (en) * | 2003-06-04 | 2004-12-16 | Serfontein, Willem, Jacob | Nutritional compositions and use thereof |
| PL214402B1 (en) * | 2003-08-11 | 2013-07-31 | Tomasz Byrski | Pharmaceutical compound, application of selenium or its compounds as well as the method for reducing breast or ovary cancer hazard |
| US20070026090A1 (en) * | 2003-09-05 | 2007-02-01 | Oren Tirosh | Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium |
| US8871715B2 (en) * | 2005-10-14 | 2014-10-28 | Alltech, Inc. | Use of selenium compounds, especially selenium yeasts for altering cognitive function |
| CN102764279B (en) * | 2005-10-14 | 2015-04-01 | 全面技术公司 | Method and composition for modifying cyte functions |
| US20100247679A1 (en) * | 2006-04-24 | 2010-09-30 | Alltech, Inc. | Methods and compositions for altering cell function |
| WO2008144543A2 (en) * | 2007-05-18 | 2008-11-27 | Alltech, Inc. | Compositions and methods for establishing and/or maintaining pregnancy |
| NZ583025A (en) | 2007-07-31 | 2012-06-29 | Univ Texas | Micro-rnas that control myosin expression and myofiber identity |
| US8796241B2 (en) * | 2007-08-29 | 2014-08-05 | Adam Lubin | Therapy of tumors and infectious agents deficient in methylthioadenosine phosphorylase |
| JP5318108B2 (en) * | 2007-10-16 | 2013-10-16 | アクチゲノミクス エス エイ | Composition for controlling lipid metabolism |
| CN101579355B (en) * | 2009-05-27 | 2010-12-08 | 徐建兴 | Nutrition composition used for maintaining functions of mitochondria and application thereof |
| PE20121709A1 (en) * | 2009-10-22 | 2012-12-17 | Propanc Pty Ltd | A PHARMACEUTICAL COMPOSITION TO TREAT CANCER INCLUDING TRYPSINOGEN AND / OR CHEMOTRIPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VAINILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCING AGENT |
| US8883498B2 (en) * | 2010-04-22 | 2014-11-11 | Kyoto University | Method for inducing differentiation of pluripotent stem cells into skeletal muscle or skeletal muscle progenitor cells |
| KR20120048205A (en) * | 2010-11-05 | 2012-05-15 | 한국식품연구원 | Composition for prevention and treatment of obesity and metabolic diseases comprising methylselenocysteine |
| KR102100091B1 (en) | 2011-04-13 | 2020-04-14 | 아지노모토 가부시키가이샤 | Nutritional composition |
-
2014
- 2014-03-14 SG SG11201507061XA patent/SG11201507061XA/en unknown
- 2014-03-14 BR BR112015022514A patent/BR112015022514A2/en not_active Application Discontinuation
- 2014-03-14 CN CN201480028372.3A patent/CN105377271A/en active Pending
- 2014-03-14 WO PCT/US2014/029328 patent/WO2014144776A1/en active Application Filing
- 2014-03-14 KR KR1020157029100A patent/KR102245702B1/en active IP Right Grant
- 2014-03-14 SG SG10202101918RA patent/SG10202101918RA/en unknown
- 2014-03-14 CN CN202210387608.9A patent/CN114984038A/en active Pending
- 2014-03-14 JP JP2016503061A patent/JP6313418B2/en active Active
- 2014-03-14 EP EP14762675.8A patent/EP2968404A4/en active Pending
- 2014-03-14 AU AU2014228785A patent/AU2014228785B2/en active Active
- 2014-03-14 US US14/776,307 patent/US9833486B2/en active Active
- 2014-03-14 CN CN202210024252.2A patent/CN114533753A/en active Pending
- 2014-03-14 MX MX2015013275A patent/MX359626B/en active IP Right Grant
- 2014-03-14 RU RU2015139742A patent/RU2663127C2/en active
- 2014-03-14 CA CA2903845A patent/CA2903845C/en active Active
-
2015
- 2015-09-11 ZA ZA2015/06759A patent/ZA201506759B/en unknown
- 2015-09-14 CL CL2015002677A patent/CL2015002677A1/en unknown
-
2016
- 2016-04-20 HK HK16104529.4A patent/HK1216506A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN114533753A (en) | 2022-05-27 |
| MX359626B (en) | 2018-10-01 |
| EP2968404A4 (en) | 2017-01-04 |
| CA2903845C (en) | 2022-08-23 |
| JP2016516058A (en) | 2016-06-02 |
| AU2014228785B2 (en) | 2018-01-25 |
| JP6313418B2 (en) | 2018-04-18 |
| WO2014144776A1 (en) | 2014-09-18 |
| MX2015013275A (en) | 2015-12-11 |
| KR102245702B1 (en) | 2021-04-28 |
| ZA201506759B (en) | 2017-03-29 |
| AU2014228785A1 (en) | 2015-09-24 |
| RU2015139742A (en) | 2017-04-21 |
| BR112015022514A2 (en) | 2017-07-18 |
| CN114984038A (en) | 2022-09-02 |
| NZ711842A (en) | 2021-04-30 |
| SG10202101918RA (en) | 2021-03-30 |
| US9833486B2 (en) | 2017-12-05 |
| US20160113977A1 (en) | 2016-04-28 |
| CN105377271A (en) | 2016-03-02 |
| RU2663127C2 (en) | 2018-08-01 |
| CL2015002677A1 (en) | 2016-12-09 |
| KR20150132374A (en) | 2015-11-25 |
| EP2968404A1 (en) | 2016-01-20 |
| HK1216506A1 (en) | 2016-11-18 |
| CA2903845A1 (en) | 2014-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1216506A1 (en) | Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction | |
| HK1250910A1 (en) | Combination of vaccination and inhibition of the pd-1 pathway | |
| IL256624B (en) | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| IL242483B (en) | Omomyc compositions and the use thereof for the treatment of cancer | |
| HK1221874A1 (en) | Use of a composition comprising fish oil and juice for the treatment and or post treatment of cancer | |
| EP2961420A4 (en) | Methods and compositions for the prevention or treatment of barth syndrome | |
| IL244622A0 (en) | Compositions for the treatment of hypertension and/or fibrosis | |
| HK1220374A1 (en) | Compositions and methods for the treatment of carboxyhemoglobinemia | |
| IL244621A0 (en) | Compositions for the treatment of hypertension and/or fibrosis | |
| EP2964750A4 (en) | Methods and compositions for the treatment and/or prevention of type 1 diabetes | |
| HK1225994A1 (en) | Compositions for use in the treatment of allergic conditions | |
| EP2948219A4 (en) | Targeting the steroidogenic pathway for treating and/or preventing allergic diseases | |
| IL259383A (en) | Compound for use in the prevention and treatment of neurodegenerative diseases | |
| PL2862576T3 (en) | Microorganisms and compositions comprising them for use in the treatment or prevention of mastitis | |
| IL245998A0 (en) | Pharmaceutical compositions and methods for the treatment and prevention of metastatic cancer | |
| PL3041459T3 (en) | Compositions useful in the prevention or treatment of skin cancer | |
| GB201316698D0 (en) | Use of tri-substituted glycerol compounds for prevention and treatment of allo-immune disorders |